期刊文献+

新疆地区58例恶性黑色素瘤临床及病理初步分析 被引量:3

Clinical and pathlogical analysis of 58 cases with maliganant melanoma in Xinjiang
下载PDF
导出
摘要 目的探讨新疆地区恶性黑色素瘤的临床及病理特征。方法回顾性分析我院(2005~2011)年经病理及免疫组化确诊的58例恶性黑色素瘤患者病例。结果 58例恶性黑色素瘤患者中男性27例(46.6%),女性31例(53.4%),男女之比:1∶1.15;发病年龄(22~94)岁,平均57.5岁,其中≤40岁8例(13.8%),(40~60)岁23例(39.7%),≥60岁27例(46.5%);发病部位在皮肤42例(72.4%),黏膜16例(27.6%),其中25例(43.1%)原发部位在四肢,其中上肢7例,下肢18例;58例患者44例(75.9%)行手术治疗,其中19例(43.2%)术后联合放化疗;病理形态上肿瘤以多种细胞类型和组织形态混合存在为主要特点,且58例患者均经免疫组化确诊。结论该地区恶性黑色素瘤多为中老年人,性别差异小,四肢皮肤为好发部位,其中下肢发病高于上肢;恶黑临床表现多样化,组织结构复杂,确诊主要依赖病理检查确诊,目前治疗仍以手术为主。 Objective To study the clinical and pathological features of malignant melanoma in Xinjing. Methods The clinical data of 58 cases with malignant melanoma in our hospital from 2005 to 2011 were collected and retrospectively analyzed. Results of 58 patients with malignant melanoma, male were of 46.6% , female were of 53.4% , and the ratio of male to female was 1 : 1.15. The age of onset was from 22 to 94 years, and the mean age was 57.5 years old. Onset in 13.8% cases occurred before age 40, in 39.7% age 40-60 years and in 46.5% after age 60 years. The tumor location was in skin (72.4%) and mucosa (27.6%) , in which 43.1% were on the upper and lower extremities. 44 cases of malignant melanoma were treated surgically, and 19 cases were treated combining with chemot- hearapy. The major pathological features were divese cell type with morphology, and all of the patients were diagnosed by immunohisto- chemistry staining examination. Conclusion malignant melanoma chiefly occurred in middle and old-aged people in Xinjiang. Most of the lesion was on the upper and lower extremities. The clinical manifestation was various and tissue structure was complicated. Diagnosis of this disease deoends on the histoDatholo^ical examination. Surzerv should be choosen as the main treatment.
出处 《皮肤病与性病》 2012年第3期133-134,137,共3页 Dermatology and Venereology
关键词 恶性黑色素瘤 临床 病理 Malignant melanoma Clinic Pathology
  • 相关文献

参考文献9

  • 1Goldstein AM, Tucker MA. Genetic epidemiology of cutaneous mela- noma: a global perspective [J]. Arch Dermatol, 2001, 137( 11 ) : 1493 - 1496.
  • 2Kim C J, Dessureauh S, Gabrilovich D, et al. Immunotherapy for mel- anoma [ J]. Cancer Control, 2002,9( 1 ): 22-30.
  • 3Daniotti M, Ferrari A, Frigerio S, et al. Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT [Jl. J Invest Dermatol, 2009, 129(7) : 1759-1768.
  • 4Rager EL, Bridgeford EP, Ollila DW. Cutaneous melanoma: update on prevention, screening, diagnosis, and treatment [J~. Am Fam Physician, 2005, 72(2): 269-276.
  • 5Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008 [J]. CA Cancer J Clin, 2008, 58(2) : 71-96.
  • 6练炼,马德亮,陶敏.恶性黑色素瘤的分子靶向治疗进展[J].实用肿瘤杂志,2010,25(2):109-112. 被引量:13
  • 7郭智俊,黄美云,肖宁新.恶性黑色素瘤86例临床病理分析[J].医学研究杂志,2008,37(9):87-89. 被引量:7
  • 8韩睿,程浩,朱可建.恶性黑素瘤38例临床分析[J].中国皮肤性病学杂志,2007,21(8):477-478. 被引量:5
  • 9Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004 [J] CA Cancer J Clin, 2004, 54(1) : 8-29.

二级参考文献42

  • 1王刚.恶性黑素瘤预后的评估[J].国外医学(皮肤性病学分册),1994,20(2):76-78. 被引量:2
  • 2Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer [J]. J Clin Oncol,2006,24( 1 ) :25 -35.
  • 3Gajewski TF, Niedzwiecki D, Johnson J, et al. Phase Ⅱ study of the farnesyltransferase inhibitor R115777 in advanced melanoma : CALGB 500104 [ J ]. J Clin Oncol, 2006,24( 18 Suppl) :8014.
  • 4Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase Ⅱ randomised discontinuation trial analysis [J]. Br J Cancer,2006,95 (5) :581 -586.
  • 5Flaherty KT, Schiller J, Schuchter LM, et al. A Phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel [J]. Clin Cancer Res ,2008,14 ( 15 ) : 4836 - 4842.
  • 6Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity [J]. Proc Natl Acad Sci USA, 2008,105 ( 8 ) : 3041 - 3046.
  • 7Fecher LA, Amaravadi R, Schuchter LM. Effectively targeting BRAF in melanoma: a formidable challenge [J]. Pigment Cell Melanoma Res,2008,21 (4) : 410 - 411.
  • 8Haass NK, Sproesser K, Nguyen TK, et al. The mitogenactivated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel [J]. Clin Cancer Res, 2008,14( 1 ) : 230 -239.
  • 9Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmaeokinetic and pharmaeodynamic study of the oral, small-molecule mitogen-activated protein kinase kiuase I/ 2 inhibitor AZD6244 ( ARRY-142886 ) in patients with advancedcancers [J]. J Clin Oncol,2008,26 ( 13 ) : 2139 - 2146.
  • 10Margolin K, Longmate J, Baratta T, et al. CCI-779 in metastatic melanoma: a Phase Ⅱ trial of the California Cancer Consortium [ J ]. Cancer,2005,104 (5) : 1045 - 1048.

共引文献22

同被引文献19

  • 1张德芳,张智武,孙凤玲.恶性黑色素瘤136例临床与病理分析[J].陕西医学杂志,2008,37(12):1684-1685. 被引量:6
  • 2胡文浩,李峰,潘晓玲,曹裕文,王海明.恶性黑色素瘤的病理及免疫组化诊断[J].石河子医学院学报,1996,18(1):1-3. 被引量:4
  • 3Rosai J.阿克曼外科病理学[M].9版.北京:北京大学医学出版社,2006:625-9.
  • 4Leboit PE,Burg G,Weedon D,等.皮肤肿瘤病理学和遗传学[M].廖松林主译.北京:人民卫生出版社,2006.20.
  • 5博洛格尼,乔伊佐,拉皮尼.皮肤病学[M].2版.朱学骏译.北京:北京大学医学出版社,2011:237-254.
  • 6刘彤华.诊断病理学[M].3版.北京:人民卫生出版社,2013:642-721.
  • 7麦中基,卡隆赫,格兰特尔.皮肤病理学(上下卷)[M].朱学骏,孙建方,译.3版.北京:北京大学医学出版社,2007:1252-1253,1260.
  • 8KoCJ,BarrRJ.皮肤病理快速诊断图谱[M].顾军,毕新岭,译,2版.北京:人民卫生出版社,2013:123.
  • 9BusamKJ.皮肤病理学[M3.黄勇,薛德彬,黄文斌,译.北京:北京科学技术出版社,2015:473-474.
  • 10Martin V, Banff S, Bordoni A, et al. Presence of cytogenetic abnor malities in Spitz naevi: a diagnostic challenge for fluorescence in- situ hybridization analysis [J]. Histopathology, 2012, 60 (2) : 336- 346.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部